Closure of patent foramen ovale versus medical therapy after cryptogenic stroke

New England Journal of Medicine

Volumn 368, Issue 12, 2013, Pages 1092-1100

  Carroll, John D ^a   Saver, Jeffrey L ^b   Thaler, David E ^c   Smalling, Richard W ^d   Berry, Scott ^e   MacDonald, Lee A ^f   Marks, David S ^g   Tirschwell, David L ^h   Pelech, Andrew N ⁱ  

^a UNIVERSITY OF COLORADO   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c TUFTS UNIVERSITY   (United States)

^d UNIVERSITY OF TEXAS   (United States)

^e BERRY CONSULTANTS   (United States)

^f Swedish Medical Center   (United States)

^g MEDICAL COLLEGE OF WISCONSIN   (United States)

^h UNIVERSITY OF WASHINGTON   (United States)

ⁱ NONE

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; CLOPIDOGREL; DIPYRIDAMOLE; WARFARIN;

ADULT; ARTICLE; BACTERIAL ENDOCARDITIS; BLEEDING; BRAIN ISCHEMIA; CEREBROVASCULAR ACCIDENT; CHEST TIGHTNESS; COHORT ANALYSIS; CONTROLLED STUDY; DEATH; DEEP VEIN THROMBOSIS; FEMALE; HEART ATRIUM FIBRILLATION; HEART ATRIUM FLUTTER; HEART SURGERY; HEART TAMPONADE; HEART VENTRICLE TACHYCARDIA; HEMATOMA; HUMAN; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; MEDICAL DEVICE COMPLICATION; MULTICENTER STUDY; PATENT FORAMEN OVALE; PERICARDIAL EFFUSION; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE; SEPSIS; SEPTAL OCCLUDER; THROMBUS;

EID: 84875192540     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa1301440     Document Type: Article

References (19)

1. Agarwal S, Bajaj NS, Kumbhani DJ, Tuzcu EM, Kapadia SR. Meta-analysis of transcatheter closure versus medical therapy for patent foramen ovale in prevention of recurrent neurological events after presumed paradoxical embolism. JACC Cardiovasc Interv 2012;5:777-89.
2. Kitsios GD, Dahabreh IJ, Abu Dabrh AM, Thaler DE, Kent DM. Patent foramen ovale closure and medical treatments for secondary stroke prevention: a systematic review of observational and randomized evidence. Stroke 2012;43:422-31.
3. Furlan AJ, Reisman M, Massaro J, et al. Closure or medical therapy for cryptogenic stroke with patent foramen ovale. N Engl J Med 2012;366:991-9.
4. Anzai H, Child J, Natterson B, et al. Incidence of thrombus formation on the CardioSEAL and the Amplatzer interatrial closure devices. Am J Cardiol 2004;93:426-31. (Pubitemid 38221349)
5. Amin Z, Hijazi ZM, Bass JL, Cheatham JP, Hellenbrand W, Kleinman CS. PFO closure complications from the AGA registry. Catheter Cardiovasc Interv 2008;72:74-9. (Pubitemid 352008987)
6. Staubach S, Steinberg DH, Zimmermann W, et al. New onset atrial fibrillation after patent foramen ovale closure. Catheter Cardiovasc Interv 2009;74:889-95.
7. Krumsdorf U, Ostermayer S, Billinger K, et al. Incidence and clinical course of thrombus formation on atrial septal defect and patent foramen ovale closure devices in 1,000 consecutive patients. J Am Coll Cardiol 2004;43:302-9. (Pubitemid 38201160)
8. Kerut EK, Norfleet WT, Plotnick GD, Giles TD. Patent foramen ovale: a review of associated conditions and the impact of physiological size. J Am Coll Cardiol 2001;38:613-23. (Pubitemid 32835725)
9. Webster MW, Chancellor AM, Smith HJ, et al. Patent foramen ovale in young stroke patients. Lancet 1988;2:11-2.
10. Silvestry FE, Kerber RE, Brook MM, et al. Echocardiography-guided interventions. J Am Soc Echocardiogr 2009;22:213-31. [Erratum, J Am Soc Echocardiogr 2009;22:336.]
11. Sacco RL, Adams R, Albers G, et al. Guidelines for prevention of stroke in patients with ischemic stroke or transient ischemic attack: a statement for healthcare professionals from the American Heart Association/American Stroke Association Council on Stroke: co-sponsored by the Council on Cardiovascular Radiology and Intervention: the American Academy of Neurology affirms the value of this guideline. Stroke 2006;37:577-617. (Pubitemid 43732031)
12. Toole JF, Lefkowitz DS, Chambless LE, Wijnberg L, Paton CC, Heiss G. Self-reported transient ischemic attack and stroke symptoms: methods and baseline prevalence: the ARIC Study, 1987-1989. Am J Epidemiol 1996;144:849-56. (Pubitemid 26374954)
13. Karanjia PN, Nelson JJ, Lefkowitz DS, et al. Validation of the ACAS TIA/stroke algorithm. Neurology 1997;48:346-51. (Pubitemid 27087601)
14. The Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Investigators. High-dose atorvastatin after stroke or transient ischemic attack. N Engl J Med 2006;355:549-59.
15. CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 1996;348:1329-39.
16. Thaler DE, Wahl A. Critique of closure or medical therapy for cryptogenic stroke with patent foramen ovale: the hole truth? Stroke 2012;43:3147-9.
17. Meier B, Kalesan B, Mattle HP, et al. Percutaneous closure of patent foramen ovale in crytogenic embolism. N Engl J Med 2013;368:1083-91.
18. Kramer P. On horse sense and horse feathers: an argument against insistence on enrolling cryptogenic stroke patients with patent foramen ovale in randomized clinical trials. Catheter Cardiovasc Interv 2007;69:1-3. (Pubitemid 46052581)
19. International Conference on Harmonization. Guidance for industry: E9 statistical principles for clinical trials, 1998 (http://www.fda.gov/downloads/ Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm073137.pdf).